RKVTF (Rakovina Therapeutics) ROCE %: -326.08% (As of Mar. 2026)


RKVTF Rakovina Therapeutics Inc RKVTF
34 GF Score
Price $0.09
! 1 Warning Sign
View Full Analysis

What is Rakovina Therapeutics ROCE %?

Rakovina Therapeutics RKVTF 34 ROCE % is -326.08% as of Mar. 2026. GuruFocus rates RKVTF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Rakovina Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -326.08%.

Rakovina Therapeutics  (OTCPK:RKVTF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Rakovina Therapeutics ROCE % Related Terms

Rakovina Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Rakovina Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rakovina Therapeutics ROCE % Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
-28.96 -37.00 -45.04 -79.24 -303.39

Rakovina Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -251.41 -341.86 -175.75 -326.77 -326.08
RKVTF
34GF Score
Rakovina Therapeutics Inc RKVTF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rakovina Therapeutics ROCE % Calculation

Rakovina Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-5.998/( ( (4.381 - 1.363) + (3.074 - 2.138) )/ 2 )
=-5.998/( (3.018+0.936)/ 2 )
=-5.998/1.977
=-303.39 %

Rakovina Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-4.588/( ( (3.074 - 2.138) + (3.059 - 1.181) )/ 2 )
=-4.588/( ( 0.936 + 1.878 )/ 2 )
=-4.588/1.407
=-326.08 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -326.08% mean?
Rakovina Therapeutics (RKVTF) has a ROCE % of -326.08% as of Mar. 2026.
Is Rakovina Therapeutics' ROCE % too high?
Rakovina Therapeutics' current ROCE % is -326.08%. Overall, Rakovina Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Rakovina Therapeutics' ROCE % compare to VRTX and REGN?
Rakovina Therapeutics' ROCE % of -326.08% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Rakovina Therapeutics's current ROCE % is -326.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rakovina Therapeutics stock overvalued right now?
Rakovina Therapeutics (RKVTF) has a current ROCE % of -326.08%. The current ROCE % is -326.08%. Rakovina Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Rakovina Therapeutics (RKVTF), the current ROCE % is -326.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rakovina Therapeutics Business Description

Other Exchanges 7JO0:GermanyRKV:Canada
Address 999 West Broadway, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a greater pace. The company has established a pipeline of distinctive DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Its drug development pipeline consists of candidates like kt-5000AI, kt-2000AI, and kt-3283, targeting solid tumours and PARP-resistant adult and childhood cancers.
34GF Score

Get the complete analysis for RKVTF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price